Actively Recruiting
Study of Alterations in Tumor Metabolism Associated With the Development of Immunotherapy Resistance in Melanoma
Led by Centre Hospitalier Universitaire de Nice · Updated on 2025-12-31
20
Participants Needed
1
Research Sites
335 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Among the mechanisms responsible for resistance to immunotherapy, metabolism seems to play a major role. A better understanding of tumor metabolism appears to be absolutely necessary in order to propose efficient therapeutic alternatives to target tumor cells without exerting a deleterious effect on the cells responsible for the anti-tumor immune response. The main objective is to evaluate metabolism modulations in melanoma cells extracted from metastases of patients sensitive and resistant to immunotherapies (anti-PD1 or anti-PD1+anti-CTLA4).
CONDITIONS
Official Title
Study of Alterations in Tumor Metabolism Associated With the Development of Immunotherapy Resistance in Melanoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female or male, 18 years of age or older
- Stage III unresectable or histologically confirmed stage IV cutaneous melanoma, treatment naive at metastatic stage, starting immunotherapy
- Performance Status 1 or better
- BRAF status available (required but any status eligible)
- Effective contraception for women of childbearing potential during study
- Affiliated to social security plan
- Signed informed consent
You will not qualify if you...
- Breastfeeding or pregnant patients
- Patients with ocular or mucosal melanoma or metastatic ocular melanoma
- Metastatic melanoma patients not treated with immunotherapy
- Contraindications to immunotherapy including HIV, HCV, HBV positive status, active autoimmune disease, or autoimmune motor neuropathy
- Vulnerable patients (minors, adults under guardianship or curatorship, deprived of liberty)
- Psychiatric or addiction history compromising consent or protocol adherence
- Any clinical condition that could interfere with study results or patient safety as judged by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Nice
Nice, Alpes-maritimes, France, 06001
Actively Recruiting
Research Team
M
Montaudie Henri
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here